Navigation Links
QuatRx Pharmaceuticals to Present at 26th Annual JP Morgan Healthcare Conference
Date:1/4/2008

QuatRx CEO will present an update on QuatRx clinical development programs including review of positive results from the Phase 3 pivotal trial for

Ophena(TM) (ospemifene)

ANN ARBOR, Mich., Jan. 4 /PRNewswire/ -- QuatRx Pharmaceuticals Company today announced that the company chief executive officer, Robert L. Zerbe, M.D., will be a presenter at the 26th Annual JP Morgan Healthcare Conference on Tuesday, January 8th, 2008, at 9:30 a.m., Pacific Time. The conference will be held at the Westin St. Francis Hotel in San Francisco from January 7 to 10, 2008.

Dr. Zerbe will present an update on clinical development programs at QuatRx including a review of the positive results from a pivotal phase 3 trial for Ophena(TM) (ospemifene) for the treatment of postmenopausal vaginal syndrome (PVS). Results of the pivotal phase 3 trial for Ophena(TM) were announced by QuatRx on January 3, 2008.

About QuatRx

QuatRx Pharmaceuticals is focused on the discovery, licensing, development and commercialization of compounds in the endocrine, metabolic and cardiovascular therapeutic areas. In addition to Ophena(TM), QuatRx has three other product candidates in active clinical development and two preclinical development programs. Fispemifene is a new selective estrogen receptor antagonist that is in Phase 2 studies as an oral treatment for the symptoms of secondary hypogonadism in men. QRX-431, a novel, selective thyroid receptor beta agonist, is in Phase 1 studies as a potential treatment for lipid disorders and obesity. Asord(TM) (becocalcidiol), a novel Vitamin D analogue, is in Phase 2 clinical trials for the treatment of psoriasis through QuatRx's partner, CollaGenex Pharmaceuticals, Inc. QuatRx's two preclinical small molecule programs are designed to address common endocrine disorders in women and men. In Europe, QuatRx operates through its Finnish subsidiary, Hormos Medical Ltd, located in Turku, Finland. For press releases
'/>"/>

SOURCE QuatRx Pharmaceuticals Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... Histogen, Inc., a regenerative medicine ... cells grown under simulated embryonic conditions, will present ... for melanoma during the 2015 Society of Investigative ... 2015 in Atlanta, GA. , Histogen has previously ... material with anti-oncologic properties, with potential benefit in ...
(Date:5/6/2015)... The Remedy Group , the premier provider ... pharmacy industry, will be exhibiting, presenting, and is a ... The Summit will be held May 4-8, 2015 at ... largest annual gathering for the specialty pharmacy industry. Thousands ... pharma/biotech manufacturers, and payers, to learn more about the ...
(Date:5/5/2015)... Mass. , May 5, 2015  Blueprint ... closing of its initial public offering of 9,367,708 ... price of $18.00 per share, including shares of ... the underwriters of their option to purchase additional ... offering to Blueprint Medicines were approximately $168.6 million, before ...
(Date:5/5/2015)... Roka Bioscience, Inc. (NASDAQ: ROKA ), a molecular diagnostics ... of foodborne pathogens,  today announced that Paul G. Thomas ... 2015 Health Care Conference on May 12 at 8:00am PT. ... Las Vegas NV. ... the investor relations section of Roka Bioscience,s website at ...
Breaking Biology Technology:Novel Immunomodulatory Treatment Induces Apoptosis in Melanoma 2The Remedy Group presenting at the 2015 Armada Specialty Pharmacy Summit: The Pitfalls to Growth and Maintaining the Patient Experience 2Blueprint Medicines Announces Closing of Initial Public Offering 2
... (Nasdaq: KOSN ) today reported financial results for the,quarter ... the quarter and year ended December 31, 2007 were $9.5,million ... to $4.6,million and $29.5 million, or $0.13 and $0.88 per ... were $5.6 million and $22.7 million for the quarter and ...
... Consecutive Quarter of Double-Digit Year-over-Year Revenue Increases, from Antibody ... 20% Year-over-Year Growth in ... Strategic Diagnostics,Inc. (Nasdaq: SDIX ) - reported ... were $7.3 million, an increase of 4% over the ...
... RAPIDS, Mich., Feb. 28 The Center for Molecular,Medicine ... laboratories in the,nation to offer a new, FDA-approved test ... The CMM (http://www.cmmdx.org ) is offering the ... a vital new tool in managing,patients with metastatic prostate ...
Cached Biology Technology:Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook 2Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook 3Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook 4Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook 5Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook 6Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results 2Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results 3Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results 4Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results 5Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results 6Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results 7Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results 8Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results 9Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results 10Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results 11Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results 12Center for Molecular Medicine Among First to Offer New FDA-Approved Test to Aid in Treatment of Prostate Cancer 2
(Date:3/26/2015)... 26, 2015 The Granite Club, ... and athletic club, today announced it has implemented a ... of movement for members and staff, while restricting access ... process, we selected FST,s IMID Access system because it ... our members and staff, in addition to unparalleled security," ...
(Date:3/24/2015)... and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has announced the addition ... Report" report to their offering. This report analyzes ... by the following Segments: Face Biometrics, and Voice Biometrics. The report ... , Japan , Europe , ... & Africa , and Latin America ...
(Date:3/24/2015)... Fla. , March 24, 2015   ... management solutions, today announced that its U.are.U ® ... accessory retailer Goorin Bros . to achieve ... biometrics-based solution secures access to the POS terminal, ... increased risk of data breaches. ...
Breaking Biology News(10 mins):Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... integral part of U.S. agriculture. Nearly $200 million of ... the facilities play a vital role in producing seeds ... healthy can translate to increased revenue for producers. ... and Christopher R. Little of Kansas State University (Manhattan) ...
... Liverpool will lead a 4 million study to analyse the ... how living cells function. Many proteins that have ... and signalling proteins, were first discovered through the study of ... have been originally isolated on the skins of grapes. ...
... WI, February 16, 2009 -- Grasslands in the Conservation ... increasingly converted to growing bioenergy grain crops. Questions abound ... during the CRP program by perennial grasses if the ... potential effectiveness of no-till production systems to conserve the ...
Cached Biology News:Detecting disease in greenhouse plants 2Scientists study full protein content of 'baker's yeast' 2Will large amounts of soil carbon be released if grasslands are converted to energy crops? 2
Glucagon-like peptide-1 (GLP-1 (1-36) amide)...
Complement factor B (human)...
... The JNK (c-Jun NH2-terminal kinase) signal ... identified MAP kinase pathways in mammals. ... to environmental stress, is associated with ... and is implicated in the immune ...
... near- and far-infrared range FT-IR spectrometers give ... their class. Yet all this comes at ... throughput: Having a larger and faster ... other conventional FT-IRs provides 300%,larger solid angle ...
Biology Products: